Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IonoChem

Financiado

Cerrado

IonoChem A new and highly efficient cross membrane drug delivery strategy

Many drugs are designed to target molecules inside cells. Due to the hydrophobic nature of the cell membranes however not all types of drugs can enter the cells in sufficient quantities. Thus large amounts of drug need to be admin... ver más

29/02/2016

ION

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

Ionovation GmbH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-02-29

NMP-25-2015-1: Accelerating the uptake of nanotech...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

ION

50.00K€ | Lider

GALOL

262.83K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DIN2021-011799 Diseño y desarrollo de nuevos lípidos con aplicación a la fo... 62K€ Cerrado

QARGO Quantitative modeling of cargo carrier biogenesis for model... 161K€ Cerrado

MOSUDO Water and Drug Mobility at Silica Surfaces probed with DOSY... 185K€ Cerrado

MOCHA Commercial feasibility of triggered liposomal drug delivery... 157K€ Cerrado

"""RTILS-GELS""" Novel Delivery Platform for Hydrophobic Drugs 309K€ Cerrado

TARGETMV TARGET MV Proof of concept study to commercialise a microve... 159K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2015-08-07
Fecha Fin: 2016-02-29

Líder del proyecto

Ionovation GmbH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Many drugs are designed to target molecules inside cells. Due to the hydrophobic nature of the cell membranes however not all types of drugs can enter the cells in sufficient quantities. Thus large amounts of drug need to be administered which can lead to highly toxic systemic effects for the patient. Furthermore, new classes of therapeutics such as RNA- and DNA-based drugs require advanced delivery techniques to reach their intracellular targets. Ionovation’s proprietary IonoChem technology will provide a novel and highly effective solution to this problem by adding lipohilic tails directly to drug molecules at a one-on-one ratio. These tails allow drugs to easily pass through the cell membrane. As part of a service offer Ionovation will work with clients to identify the most effective tail for a particular molecule, and will also perform the lipophilization. The IonoChem platform will enable Ionovation GmbH (a manufacturer of experimental set-ups for the analysis of biological membranes) to enter the market for drug delivery technologies, thus creating a new line of business for the company. IonoChem will target the market for drug delivery systems, which was valued at US$151 billion in 2013. Market segments for initial introduction of the technology include RNAi drug delivery (a market worth US $11,7 billion in 2013) and drugs withdrawn from the market (eg Vioxx with 2.5 billion US $ annual global sales). Objectives of the phase I project include analysis of customer needs (pricing, expected turn-around times etc.), refinement of business model (licensing/fee for use model for contract manufacturers vs. service offer with production facilities at Ionovation’s head quarters); search for a suitable contract manufacturer for the phase II activities and the elaboration of a business plan. Phase II objectives include upscaling of the production under GMP conditions, establishment of contact to customers and the qualification of IonoChem in a preclinical setting.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores